StockMarketWire.com - Liberum Capital has upgraded its investment rating on Plant Health Care [LON:PHC] to buy from hold after the agricultural bio-technology company announced two more evaluation agreements for its peptide technology platform, Innatus 3G.

The broker highlighted that four of the six major agrochemical companies have now signed agreements.

Liberum added: "PHC's investment case rests predominantly on its R&D. The signing of four agreements since April and a fall in the share price drives our upgrade to Buy."

Analysts have left their target price unchanged at 120 pence a share.




At 4:21pm: [LON:PHC] Plant Health Care PLC share price was +0.5p at 93p



Story provided by StockMarketWire.com